title: Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?
authors.affiliation: Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Gartrell
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives*; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010669:Phenylthiohydantoin; D007610:Kallikreins; D017430:Prostate-Specific Antigen